奥氮平与利培酮治疗女性精神分裂症的对照研究

目的：奥氮平与利培酮对女性精神分裂症的疗效及不良反应。方法：将符合CCMD-3精神分裂症诊断标准的67例女性患者随机分为两组，分别给予奥氮平与利培酮治疗，疗程为8周。以阳性和阴性症状量表（PANSS）、临床疗效总评量表（CGI）评定疗效，以精神药物副反应量表（TESS）评定不良反应。结果：治疗8周后，两组患者的PANSS、CGI评分均明显减少，差异有显著性（P〈0．05）。两组间比较PANSS、CGI评分差异无显著性（P〉0．05）。奥氮平组不良反应发生率低于利培酮组，差异有显著性（P〈0．05）。结论：奥氮平与利培酮对女性精神分裂症的疗效相当，有效率分别为85．3％，80．9％，奥氮平锥体外系不良反应和内分泌改变较利培酮少，更适用于女性精神分裂症患者。

Comparison of curative effect and safety of olanzapine and risperidone in the treatment of female schizophrenia

Objective:To compare the curative effect and safety of the therapy scheme to apply olanzapine and risperidone to the female schizophrenia.Methods:67 female patients with schizophrenia by CCMD-3 were randomly allocated to two groups treated with olanzapine orrisperidone for 8 weeks.We evaluate the result by the Positive and Negative Syndrome Scale for schizophrenia(PANSS),the Clinical Global Impression Scale(CGI), the Treatment Emergent Symptom Scale(TESS).Results: By the end of the 8 weeks,the PANSS and CGI scores of two groups decreased notably (P<0.05).There was no significant difference between the two groups(P>0.05).Incidence of adverse effects in the olanzapine group was lower than in the rispridone group,but the difference was not significant(P<0.05).Conclusions: The results suggest that olanzapine is as effective as risperidone for the treatment of female schizophrenia;the effective rate of the therapy scheme is 85.3% and 80.9%.The rates of extra-pyramidal symptoms and endocrine change were lower in the olanzapine group than these in the risperidone group.Olanzapine is beneficial for female schizophrenia.